Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: TheStreet.com Ratings
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Novo Nordisk A/S Reaffirms FY 2013 Guidance-Conference Call
Novo Nordisk A/S announced that for fiscal 2013, it expects sales growth of 8% to 11% and an operating profit growth of around 10%. The Company reported revenue of DKK 78.026 billion and operating profit of DKK 29.474 billion for fiscal 2012. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of DKK 84.306 billion and operating profit of DKK 30.902 billion for fiscal 2013.
Latest Developments for Novo Nordisk A/S
- Novo Nordisk A/S Announces Share repurchase programme
- Novo Nordisk A/S Presents FDA New Data Confirming No Link between Victoza and Cancer-Reuters
- Novo Nordisk A/S Reports 8% Weight Loss in Phase 3a Obesity Trial with Liraglutide 3 mg
- Novo Nordisk A/S Reports Positive Results from First Phase 3 Trial with Long-Acting Factor IX for Treatment of Haemophilia B
Latest Key Developments in Pharmaceuticals
- Bristol-Myers Squibb Co And Bristol-Myers Squibb Announces Top Line Results For SAVOR-TIMI-53 Cardiovascular Outcomes Trial Of Onglyza (saxagliptin)
- Glenmark Pharmaceuticals Ltd Receives Final ANDA Approval For Riluzole Tablets, 50mg
- Valeant Pharmaceuticals International Inc's VPII Escrow Corp Announces Launch Of Private Offering Of Senior Notes
- Share this
- Link this
- Digg this
Follow Reuters